Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
GIR-M52H3 | Mouse | Mouse GITR / TNFRSF18 Protein, His Tag |
|
||
GIR-H82E1 | Human | Biotinylated Human GITR / TNFRSF18 Protein, His,Avitag™ (MALS verified) |
|
||
GIR-C52H6 | Canine | Canine GITR / TNFRSF18 Protein, His Tag |
|
||
GIR-H82F7 | Human | Biotinylated Human GITR / TNFRSF18 Protein, Fc,Avitag™ |
|
||
GIR-H525a | Human | Human GITR / TNFRSF18 Protein, Mouse IgG2a Fc Tag, low endotoxin |
|
||
GIR-H5254 | Human | Human GITR / TNFRSF18 Protein, Fc Tag |
|
||
GIR-C5255 | Rhesus macaque | Rhesus macaque GITR / TNFRSF18 Protein, Fc Tag |
|
||
GIR-R5222 | Rat | Rat GITR / TNFRSF18 Protein, His Tag |
|
||
GIR-H5228 | Human | Human GITR / TNFRSF18 Protein, His Tag (MALS verified) |
|
Immobilized Human GITR Ligand, Fc Tag at 10 μg/mL (100 μL/well) can bind Biotinylated Human GITR, His,Avi tag™ (Cat. No. GIR-H82E1) with a linear range of 0.039-0.625 μg/mL (QC tested).
The purity of Biotinylated Human GITR Protein, His,Avitag (Cat. No. GIR-H82E1) is more than 95% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
BMS-986156 | BMS-986156 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Thoracic Neoplasms; Neoplasms; Lung Neoplasms | Details |
Ragifilimab | INCAGN-1876; INCAGN-01876; AGEN-1876; CM-701 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Neoplasms; Neoplasm Metastasis | Details |
Anti-GITR antibody (BMS) | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details | |
LY-3844583 | LY-3844583; LY3844583 | Phase 1 Clinical | Eli Lilly And Company | Dermatitis, Atopic | Details |
REGN-6569 | REGN-6569; REGN6569 | Phase 1 Clinical | Squamous Cell Carcinoma of Head and Neck | Details | |
GWN-323 | GWN-323 | Phase 1 Clinical | Novartis Pharma Ag | Solid tumours; Lymphoma | Details |
MK-4166 | MK-4166 | Phase 1 Clinical | Merck & Co Inc | Solid tumours | Details |
BMS-986156 | BMS-986156 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Thoracic Neoplasms; Neoplasms; Lung Neoplasms | Details |
Ragifilimab | INCAGN-1876; INCAGN-01876; AGEN-1876; CM-701 | Phase 2 Clinical | Agenus Inc, Ludwig Institute For Cancer Research | Neoplasms; Neoplasm Metastasis | Details |
Anti-GITR antibody (BMS) | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details | |
LY-3844583 | LY-3844583; LY3844583 | Phase 1 Clinical | Eli Lilly And Company | Dermatitis, Atopic | Details |
REGN-6569 | REGN-6569; REGN6569 | Phase 1 Clinical | Squamous Cell Carcinoma of Head and Neck | Details | |
GWN-323 | GWN-323 | Phase 1 Clinical | Novartis Pharma Ag | Solid tumours; Lymphoma | Details |
MK-4166 | MK-4166 | Phase 1 Clinical | Merck & Co Inc | Solid tumours | Details |
This web search service is supported by Google Inc.